Tagraxofusp-erzs

Phase 2Biologic

SStemline Therapeutics, Inc.

Tagraxofusp-erzs is one of 74 biologic programs targeting Chronic Myelomonocytic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myelomonocytic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaTerminated

Chronic Myelomonocytic LeukemiaPreclinical

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Terminated

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Vepesid

AAvyxa

Phase 3

52 5

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 7

Nexavar

Bayer

Phase 3

12 8

Cellcept

Roche

Phase 3

10 9

Trexall

Jazz Pharmaceuticals

Phase 3

9 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT04216524

Q1 2027

PreclinicalActive, not recruiting

Chronic Myelomonocytic Leukemia

NCT05038592

Q2 2027

Phase 1Recruiting

Acute Myeloid Leukemia

NCT06498973

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT05720988

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Terminated·SStemline Therapeutics, Inc.·Phase 1/2·NCT02270463·16 enrolled

CD123 Antibody Toxin Congregate (CD123 ATC; Tagraxofusp) Combined With Azacitidine for Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for Patients With CD123-Positive Malignant

Recruiting·CCity of Hope Medical Center·Phase 1·NCT06498973·43 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm2 trials

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04317781·3 enrolled

Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04216524·40 enrolled

Acute Lymphoblastic Leukemia1 trial

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Chronic Myelomonocytic Leukemia1 trial

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05038592·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tagraxofusp-erzs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tagraxofusp-erzs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tagraxofusp-erzs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stemline Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SStemline Therapeutics, Inc.

Tagraxofusp-erzs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Blastic Plasmacytoid Dendritic Cell Neoplasm2 trials

Acute Lymphoblastic Leukemia1 trial

Chronic Myelomonocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News